WBC Growth Factors: ASCO Guideline Update

Prophylactic use of CSFs to reduce the risk of febrile neutropenia is warranted when the risk of febrile neutropenia from chemotherapy is approximately 20% or higher and no other equally effective and safe regimen that does not require CSFs is available. For patients receiving chemotherapy with a <20% risk of febrile neutropenia, primary prophylaxis with a CSF may be warranted if patients are at a high risk of febrile neutropenia based on age, medical history, or disease characteristics. For stem-cell mobilization, CSFs may be used either alone, after chemotherapy, or in combination with plerixafor or motixafortide. The guideline also provides information about the dosing and selection of CSFs.Additional information is available at www.asco.org/supportive-care-guidelines.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2026-02-25
DOI
https://doi.org/10.1200/jco-25-02938
Primary Topic
Growth Hormone and Insulin-like Growth Factors
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

WBC Growth Factors: ASCO Guideline Update

T Cigler, Logan Roof, Jana Dickter, Bernardo Leon Rapoport et al.
Journal of Clinical Oncology
Growth Hormone and Insulin-like Growth Factors
article

WBC Growth Factors: ASCO Guideline Update

T Cigler, Logan Roof, Jana Dickter, Bernardo Leon Rapoport, Kevin Knopf, Sally Schott, Ramila Shilpakar, Thomas J. Smith, Amar H Kelkar, Dario Trapani, B. Gyawali, Madhav R. Seshadri, Amy B. Woodard, Kari Bohlke
article en

Abstract

Prophylactic use of CSFs to reduce the risk of febrile neutropenia is warranted when the risk of febrile neutropenia from chemotherapy is approximately 20% or higher and no other equally effective and safe regimen that does not require CSFs is available. For patients receiving chemotherapy with a <20% risk of febrile neutropenia, primary prophylaxis with a CSF may be warranted if patients are at a high risk of febrile neutropenia based on age, medical history, or disease characteristics. For stem-cell mobilization, CSFs may be used either alone, after chemotherapy, or in combination with plerixafor or motixafortide. The guideline also provides information about the dosing and selection of CSFs.Additional information is available at www.asco.org/supportive-care-guidelines.

Journal of Clinical OncologyVol. 44(9)
American Society of Clinical Oncology (US), Harvard University (US), University of California, San Francisco (US), University of Milan (IT), Queen's University (CA), Cornell University (US), Bir Hospital (NP), Alameda Health System (US), The Ohio State University Wexner Medical Center (US), Moffitt Cancer Center (US), The Medical Oncology Centre of Rosebank (ZA), Highland Hospital (US), City of Hope (US), Dana-Farber Cancer Institute (US), National Academy of Medical Sciences (NP), Patient Advocate Foundation (US), Sidney Kimmel Comprehensive Cancer Center (US), Weill Cornell Medicine (US), European Institute of Oncology (IT), University of Pretoria (ZA)
Partnerships for the goals
Openalex Percentile: Top 44%
Growth Hormone and Insulin-like Growth Factors
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.